Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jop P Mostert

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2019
Response to Grech et al.: FLOUX-PMS study sample considerationsJop P Mostert, Jacques De Keyser
Journal of the Neurological Sciences|October 16, 2007
Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disordersJacques De Keyser, Jop P Mostert, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2021
A comparison of clinical outcomes in PPMS in the INFORMS original trial data setMarcus W Koch, Jop P Mostert, Bernard Uitdehaag, et al.
European Radiology|January 1, 2005
1H Magnetic resonance spectroscopy of the internal capsule in human brain: a feasibility study to detect lactate following contralateral motor activityJop P Mostert, Paul E Sijens, Matthijs Oudkerk, et al.
European Radiology|July 20, 2005
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findingsPaul E Sijens, Jop P Mostert, Matthijs Oudkerk, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 3, 2008
Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significanceJacques De Keyser, Christel Steen, Jop P Mostert, et al.
Neuroscience Letters|April 29, 2006
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosisJop P Mostert, Paul E Sijens, Matthijs Oudkerk, et al.
Neurology|April 4, 2007
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesMarcus W Koch, Jop P Mostert, Joeke J de Vries, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Therapeutic potential of fluoxetine in neurological disordersJop P Mostert, Marcus W Koch, Marco Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 15, 2020
COVID-19 in multiple sclerosis: The Dutch experienceFloor C Loonstra, Elske Hoitsma, Zoé LE van Kempen, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2019
Response to Grech et al.: FLOUX-PMS study sample considerationsJop P Mostert, Jacques De Keyser
Journal of the Neurological Sciences|October 16, 2007
Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disordersJacques De Keyser, Jop P Mostert, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2021
A comparison of clinical outcomes in PPMS in the INFORMS original trial data setMarcus W Koch, Jop P Mostert, Bernard Uitdehaag, et al.
European Radiology|January 1, 2005
1H Magnetic resonance spectroscopy of the internal capsule in human brain: a feasibility study to detect lactate following contralateral motor activityJop P Mostert, Paul E Sijens, Matthijs Oudkerk, et al.
European Radiology|July 20, 2005
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findingsPaul E Sijens, Jop P Mostert, Matthijs Oudkerk, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 3, 2008
Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significanceJacques De Keyser, Christel Steen, Jop P Mostert, et al.
Neuroscience Letters|April 29, 2006
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosisJop P Mostert, Paul E Sijens, Matthijs Oudkerk, et al.
Neurology|April 4, 2007
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesMarcus W Koch, Jop P Mostert, Joeke J de Vries, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Therapeutic potential of fluoxetine in neurological disordersJop P Mostert, Marcus W Koch, Marco Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 15, 2020
COVID-19 in multiple sclerosis: The Dutch experienceFloor C Loonstra, Elske Hoitsma, Zoé LE van Kempen, et al.
Pageof 3